Core Viewpoint - The company, 医脉通 (02192), announced a mid-term dividend of HKD 0.1166 per share for the six months ending June 30, 2025, to be distributed on September 25, 2025 [1] Summary by Category - **Dividend Announcement** - The mid-term dividend is set at HKD 0.1166 per share [1] - The dividend distribution date is scheduled for September 25, 2025 [1] - The dividend pertains to the financial period ending June 30, 2025 [1]

Core Viewpoint - The company, Yimaitong (02192), reported a significant increase in revenue and profit for the six months ending June 30, 2025, indicating strong financial performance and growth potential in the healthcare sector [1]. Financial Performance - The company achieved a revenue of 312 million RMB, representing a year-on-year increase of 28.2% [1]. - The profit attributable to shareholders was 155 million RMB, which is a 5.9% increase compared to the previous year [1]. - The basic earnings per share were reported at 21.2 cents [1].

智通财经APP讯，医脉通(02192)发布公告，将于2025年9月25日派发截至2025年6月30日止六个月的中期 股息每股0.1166元。 ...

Group 1 - The company, 医脉通 (02192), reported revenue of 312 million RMB for the six months ending June 30, 2025, representing a year-on-year increase of 28.2% [1] - The profit attributable to the owners of the parent company was 155 million RMB, reflecting a year-on-year increase of 5.9% [1] - The basic earnings per share were 21.2 cents [1]

Core Viewpoint - The company, 医脉通 (02192.HK), reported significant revenue growth and profitability for the six months ending June 30, 2025, indicating strong performance in the AI healthcare sector [1] Financial Performance - Revenue reached RMB 312 million, a year-on-year increase of 28.2% [1] - Gross profit was RMB 184 million, reflecting a 24.9% increase compared to the previous year [1] - Net profit attributable to the parent company was RMB 155 million, up 5.9% year-on-year [1] - Adjusted net profit under non-Hong Kong Financial Reporting Standards was RMB 167 million, an increase of 6.9% [1] - Basic earnings per share were RMB 0.212 [1] Dividend Announcement - The board of directors declared an interim dividend of RMB 0.1166 per ordinary share [1] Business Solutions - The company generated revenue through three main solutions: precision marketing and enterprise solutions, medical knowledge solutions, and intelligent patient management solutions [1] - The company maintained a high net profit margin of 51.4% during the reporting period [1] - Adjusted net profit margin was 53.4%, reinforcing the company's leading position in the AI healthcare industry [1]

EF001 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 醫脈通科技有限公司 | | 股份代號 | 02192 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2025年6月30日止六個月之中期股息 | | 公告日期 | 2025年8月25日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 中期（半年期） | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年6月30日 | | 宣派股息 | 每 股 0.1166 RMB | | 股東批准日期 | 不適用 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 每 股 0.1277 HKD | | 匯率 | 1 RMB ...

Financial Performance - Medlive Technology Co., Ltd. reported a revenue of RMB 312,035,000 for the six months ended June 30, 2025, representing a year-on-year increase of 28.2% compared to RMB 243,443,000 in 2024[2]. - The gross profit for the same period was RMB 183,948,000, reflecting a 24.9% increase from RMB 147,329,000 in the previous year[2]. - The adjusted net profit under non-Hong Kong Financial Reporting Standards was RMB 166,738,000, a 6.9% increase from RMB 156,048,000 in the previous year[2]. - Net profit increased from RMB 152.7 million for the six months ending June 30, 2024, to RMB 160.4 million for the same period in 2025, with a net profit margin of 51.4%[9]. - Revenue for the six months ending June 30, 2025, was approximately RMB 312.0 million, representing a year-over-year growth of 28.2%[9]. - Revenue increased by approximately 28.2% from RMB 243.4 million for the six months ended June 30, 2024, to approximately RMB 312.0 million for the same period in 2025, primarily driven by growth in precision marketing and enterprise solutions[29]. - The group’s net profit increased by approximately 5.0% from RMB 152.7 million for the six months ended June 30, 2024, to approximately RMB 160.4 million for the same period in 2025, with a net profit margin of approximately 51.4%[42]. Client and User Growth - The number of medical clients for precision marketing and enterprise solutions increased to 191, up from 158 in the same period last year, indicating a growth of 20.9%[4]. - The average monthly active users rose to 2.78 million, compared to 2.50 million in the previous year, marking an increase of 11.2%[4]. - The number of clients covered by the precision marketing and enterprise solutions increased by 20.9% year-over-year, from 158 clients in the first half of 2024 to 191 clients in the first half of 2025[10]. - The number of products covered by the precision marketing solution rose by 32.4% year-over-year, from 336 products in the first half of 2024 to 445 products in the first half of 2025[10]. - Paid click-throughs increased from 5.98 million in the first half of 2024 to 7.69 million in the first half of 2025[10]. - The company has over 7 million registered users on its platform, with more than 4 million being practicing physicians, representing 88% of the total practicing physicians in China[6]. Product and Service Development - The company launched several AI-driven products, including MedSeeker, MedPaper, and MedAssister, aimed at enhancing clinical decision-making and research efficiency for physicians[7]. - The precision digital marketing demand is expected to continue growing sustainably, supported by favorable policies and technological advancements in the healthcare industry[5]. - The company has established a high-end GPU computing cluster to enhance model inference efficiency while ensuring data security[7]. - The clinical case database launched in April 2023 includes 5,000 high-quality clinical cases covering over 20 key departments[16]. - The number of clinical guidelines on the platform increased to 33,000, with an addition of over 1,800 new guidelines[16]. - The AI content review module reduced the content review cycle for pharmaceutical clients from three days to two hours[13]. - The company expanded its disease knowledge base with 1,700 disease entries and integrated the MedSeeker intelligent Q&A feature, enhancing clinical decision support for physicians[17]. - The company added over 3,200 Chinese drug instructions and dynamically updated more than 1,200 drug information entries, surpassing a total of 38,000 Chinese drug instructions[17]. Financial Management and Investments - The group held cash and cash equivalents of approximately RMB 2,942.5 million, a decrease from RMB 3,844.7 million as of December 31, 2024[47]. - The group’s debt investments amounted to RMB 1,474.7 million as of June 30, 2025, with expected annual returns ranging from 4.53% to 5.50%[48]. - The group plans to continuously purchase financial products upon maturity of existing investments to maximize returns on unutilized funds[49]. - The total liabilities related to debt investments increased significantly to RMB 966,261,000 as of June 30, 2025, compared to RMB 440,374,000 at the end of 2024[84]. - The net proceeds from the global offering, approximately HKD 4,677 million, are allocated for business expansion, technology investment, and strategic acquisitions[94]. - As of June 30, 2025, approximately RMB 900 million of the unutilized proceeds from the global offering has been used for purchasing financial products[96]. Corporate Governance - The company has complied with the corporate governance code, with the exception of the separation of the roles of Chairman and CEO[98]. - The board will continue to review and monitor the company's practices to maintain high standards of corporate governance[98]. - The company has adopted the "Standard Code of Conduct for Directors' Securities Transactions" as per the Listing Rules Appendix C3, confirming compliance by all directors during the reporting period[99]. - An Audit Committee has been established, consisting of three independent non-executive directors, with Ms. Wang Shan as the chairperson, confirming adherence to applicable accounting principles and regulations[100]. - The board of directors includes executive directors Tian Liping, Tian Lixin, Tian Lijun, and Zhou Xin, along with non-executive directors Chai Wu Ying Er and Jin Se Yi Xian, and independent non-executive directors Ye Lin, Ma Jun, and Wang Shan[103]. Research and Development - Research and development expenses increased to RMB 41,074,000, up 33.8% from RMB 30,675,000 in the prior period[76]. - The total employee cost for the six months ended June 30, 2025, was approximately RMB 98.8 million, an increase of 19.3% from RMB 82.8 million in 2024, primarily due to an increase in sales and platform development personnel[56]. - Capital expenditures for the six months ended June 30, 2025, were approximately RMB 25.1 million, compared to RMB 18.5 million in the same period of 2024, mainly for the acquisition of a 60% stake in Beijing Focus Innovation Technology Co., Ltd.[53]. - The company plans to enhance its medical knowledge solutions with an allocation of HKD 280.7 million, with expected utilization by December 2027[96]. - Investment in technology and R&D capabilities includes HKD 467.7 million for talent recruitment and expert collaboration, with a projected timeline for completion by December 2027[96].

Group 1 - The core viewpoint of the article highlights the positive impact of rising expectations for interest rate cuts in the US on the biotechnology sector, leading to a significant increase in the S&P Biotechnology Index by 2.89% [1] - The Hong Kong pharmaceutical sector continues to show strong performance, with the Hong Kong Pharmaceutical ETF (159718.SZ) rising by 0.38% [1] - Notable individual stock performances include a 6.22% increase for Simcere Pharmaceutical Group (02410), a 3.34% rise for BeiGene (06160), and a 2.29% increase for Kelun-Biotech (06990) [1] Group 2 - The liquidity in the market is robust, with the Hong Kong Pharmaceutical ETF seeing a turnover of 13.3% and a transaction volume of 36.42 million yuan within the first 20 minutes of trading [1] - Guotai Junan Securities has stated that China's innovative drugs are on the rise, entering the initial phase of realizing innovation results, with significant opportunities for independent development and large transactions through business development (BD) licensing [1] - The Hong Kong Pharmaceutical ETF focuses on 18 A-share biotechnology companies, including key innovative drug firms such as BeiGene, WuXi Biologics, and CSPC Pharmaceutical Group, benefiting from global innovation drug research dividends [1] Group 3 - The article emphasizes the favorable conditions for the innovative drug growth sector due to the anticipated US interest rate cuts, which are expected to benefit the domestic innovative drug companies as they expand internationally [1] - The recommendation is to pay attention to the Hong Kong Pharmaceutical ETF (159718.SZ) and its associated funds (Class A: 019598, Class C: 019599) as they are positioned to capitalize on these trends [1]

（股份代號：2192） 董事會會議日期 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 Medlive Technology Co., Ltd. 醫脈通科技有限公司 （於開曼群島註冊成立的有限責任公司） 醫脈通科技有限公司 董事長兼首席執行官 田立平 香港，二零二五年八月八日 於本公告日期，董事會包括執行董事田立平女士、田立新先生、田立軍先生及周欣女士； 非執行董事槌屋英二先生及金色一賢先生；以及獨立非執行董事葉霖先生、馬軍醫師及王珊 女士。 醫脈通科技有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，本公司 將於二零二五年八月二十五日（星期一）舉行董事會會議，藉以（其中包括）考 慮及批准本公司及其附屬公司截至二零二五年六月三十日止六個月之中期業績， 並考慮派發中期股息（如有）。 承董事會命 ...

金融界8月5日消息，上证指数高开高走，中证港股通医疗商业与服务综合指数 (港股通医疗商业， 931966)报1701.32点。 数据统计显示，中证港股通医疗商业与服务综合指数近一个月上涨10.64%，近三个月上涨12.75%，年 至今上涨22.94%。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在下一个定期 调整日前，权重因子一般固定不变。遇临时调整时，当中证港股通综合指数调整样本时，样本随之进行 相应调整。若中证港股通综合指数样本有特殊事件发生，导致其行业归属发生变化，指数样本进行相应 调整。当样本退市时，将其从指数样本中剔除。样本公司发生收购、合并、分拆、停牌等情形的处理， 参照计算与维护细则处理。 本文源自：金融界 作者：行情君 从指数持仓来看，中证港股通医疗商业与服务综合指数十大权重分别为：京东健康（16.57%）、阿里 健康（14.32%）、国药控股（13.85%）、平安好医生（11.27%）、上海医药（6.64%）、医脉通 （6.0%）、锦欣生殖（5.1%）、海吉亚医疗 ...